Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

PURPOSE: To determine the maximum tolerated dose (MTD) of trabectedin plus gemcitabine administered on a weekly schedule in patients with advanced solid tumors. METHODS: Patients with ECOG performance status 0–1 and adequate organ function were enrolled. On days 1, 8, and 15 of a 28-day cycle, patie...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Messersmith, Wells A., Jimeno, Antonio, Ettinger, David, Laheru, Dan, Brahmer, Julie, Lansey, Dina, Khan, Yasmin, Donehower, Ross C., Elsayed, Yusri, Zannikos, Peter, Hidalgo, Manuel
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3556988/
https://ncbi.nlm.nih.gov/pubmed/18379785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0733-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items